| Revenue growth | 18.8% YoY consolidated; 25.8% YoY standalone. |
|---|---|
| Margins | Sequential recovery to 10.9% consolidated EBITDA margin. |
| Order book | Decent order book currently for international business. |
| Demand visibility | Strong Rx growth in India; decent order book for UK/Europe. |
| Management confidence | High for international markets; recovery expected in domestic seasonal products. |
Growth
Consolidated revenue grew 18.8% YoY. Standalone EBITDA jumped to ₹630m (14.7% margin) from ₹35m YoY.
Outlook
Debt repayment target of ₹140cr/year for 3 years; focus on liquid orals in US/Europe; no major capex planned.
Risks
Substantial forex losses (₹24cr), high debt levels (₹960cr), and regulatory delays at sterile manufacturing sites.
Earnings Call filed with BSE, NSE: INDOCO. Summary written with AI assistance from the document.
Indoco Remedies Ltd: key numbers
- Share price
- ₹254.46
- Market cap
- ₹2,349 Cr
- Revenue (annual)
- ₹1,845 Cr
- Net profit (annual)
- ₹-95.14 Cr
- P/E (TTM)
- 417.2×Sector 50.4×
- Promoter holding
- 58.86%+0.00% QoQ
- FII holding
- 1.27%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indoco Remedies Ltd
All →Indoco Remedies Other Announcement
Indoco Remedies disclosed an unsolicited Crisil ESG rating of 'Crisil ESG 60'. The company notes it did not engage Crisil for the assessment.
Indoco Remedies Merger & Restructuring Worth ₹0.01 Cr
Indoco Remedies will incorporate a new wholly owned subsidiary, Warren Lifesciences Private Limited, for the pharmaceutical business with an initial capital of Rs. 1 Lakh.
- Value
- ₹0.01 Cr
Indoco Remedies Annual General Meeting
Indoco Remedies filed proceedings of its 79th AGM held on 17 September 2026. Shareholders voted on nine resolutions including dividend and borrowing limits.
Indoco Remedies Promoter Buying
Indoco Remedies promoter Aditi M. Panandikar and PAC bought 38,930 shares on the open market, raising aggregate holding to 7.30%. No transaction price is disclosed in the filing.
- Promoter stake change
- +0.04%
Indoco Remedies Promoter Buying: ₹0.92 Cr
Promoters Aditi M. Panandikar, Madhura Suresh Kare, Suresh G. Kare, and Aruna Suresh Kare acquired Indoco Remedies Ltd shares via market purchases, totaling ₹0.92 Crore.
- Value
- ₹0.92 Cr
Indoco Remedies Business Update
Indoco Remedies received seven USFDA observations in Form 483 for its Plant II (Sterile) facility in Goa following an inspection from August 27 to September 4, 2026.